Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis

Sombat Treeprasertsuk, Marina G. Silveira, Janice L. Petz, Keith D. Lindor

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


We aimed to describe the effects of parenteral bisphosphonates on bone mineral density (BMD) changes in primary biliary cirrhosis (PBC) patients with osteoporosis. Seventeen PBC patients with osteoporosis diagnosed between 1996 and 2005 were enrolled retrospectively. All patients received one of the following parenteral bisphosphonates: zoledronic acid, pamidronate disodium, or ibandronate sodium. The median (interquartile range) age of patients at osteoporosis diagnosis was 62.2 (56.4-67.9) and 94% were women. After treatment, percent change of lumbar spine bone mineral density (LS-BMD) and proximal femur BMD (PF-BMD) of patients with PBC was 2.9% and 0.4%, respectively. Eight patients (47%) showed a greater LS-BMD and/or PF-BMD with percent change of LS-BMD and PF-BMD of 8.7% and 0.8%, respectively. No serious adverse events were found. In PBC patients with osteoporosis, parenteral bisphosphonates can stabilize BMD for 47% of patients. More prospective studies are needed to evaluate the efficacy of specific parenteral bisphosphonates in patients with PBC and osteoporosis.

Original languageEnglish (US)
Pages (from-to)375-381
Number of pages7
JournalAmerican Journal of Therapeutics
Issue number5
StatePublished - Sep 2011
Externally publishedYes


  • bone disease
  • parenteral bisphosphonates
  • primary biliary cirrhosis
  • treatment

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis'. Together they form a unique fingerprint.

Cite this